International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Von Willebrand Factor (VWF) Multimer Analysis for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis
Timeframe: 12 months (confirmatory phase)
Centralized Molecular Type 3 Von Willebrand's Disease (VWD3) Diagnosis Through DNA Analysis
Timeframe: 12 months (confirmatory phase)
Record of Bleeding Episodes
Timeframe: 24 months (first prospective phase) + 24 months (second prospective phase)
Adverse Events
Timeframe: 24 months (first prospective phase) + 24 months (second prospective phase)
Type of Von Willebrand Factor / Factor VIII (VWF/FVIII)-Containing Concentrates in Use
Timeframe: 24 months (first prospective phase) + 24 months (second prospective phase)